Drug intelligence / Profile preview

ChAdOx1 nCoV-19 + paracetamol

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral

Overview

ChAdOx1 nCoV-19 + paracetamol is a COVID-19 vaccination protocol where paracetamol is administered prophylactically before and after ChAdOx1 nCoV-19 vaccination to reduce vaccine-associated reactogenicity. ChAdOx1 nCoV-19 is a replication-deficient adenoviral vector vaccine that encodes the SARS-CoV-2 spike protein to induce immune responses. Clinical studies showed that prophylactic paracetamol (1g every 6 hours for 24 hours) significantly reduced local and systemic reactions including pain, fever, chills, muscle ache, headache, and malaise while maintaining the vaccine's immunogenicity.

Targets

SARS-CoV-2 spikeCOX

Beyond the preview

Go deeper on ChAdOx1 nCoV-19 + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChAdOx1 nCoV-19 + paracetamol.

Explore the full profile